Joni Sebastiano, Shane A. McGlone, Zachary V. Samuels, Camilla Grimaldi, Ava Stoddard, Sugar Galka, Emma Colaco, Brian M. Zeglis
{"title":"Evaluating Radiotheranostic Targets for Endometrial Cancer","authors":"Joni Sebastiano, Shane A. McGlone, Zachary V. Samuels, Camilla Grimaldi, Ava Stoddard, Sugar Galka, Emma Colaco, Brian M. Zeglis","doi":"10.2967/jnumed.125.270318","DOIUrl":"https://doi.org/10.2967/jnumed.125.270318","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.270318absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"15 1","pages":"jnumed.125.270318"},"PeriodicalIF":0.0,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144899163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sanjana Ballal, Mohammad Sakir, Kunal R. Chandekar, Sameer Rastogi, Madhav P. Yadav, Frank Roesch, Madhavi Tripathi, Marcel Martin, Chandrasekhar Bal
{"title":"Efficacy and Safety of [177Lu]Lu-DOTAGA.Glu.(FAPi)2 Therapy in Patients with Sarcoma","authors":"Sanjana Ballal, Mohammad Sakir, Kunal R. Chandekar, Sameer Rastogi, Madhav P. Yadav, Frank Roesch, Madhavi Tripathi, Marcel Martin, Chandrasekhar Bal","doi":"10.2967/jnumed.125.270186","DOIUrl":"https://doi.org/10.2967/jnumed.125.270186","url":null,"abstract":"<p>The aim of this study was to evaluate the efficacy and safety of [<sup>177</sup>Lu]Lu-DOTAGA.Glu.(FAPi)<sub>2</sub> therapy in patients with sarcoma, a cohort of individuals with limited treatment options and significant disease burden. <strong>Methods:</strong> This retrospective analysis involved 10 patients with histologically confirmed sarcoma. Patients received a median cumulative activity of 17.5 GBq (range, 6.3–55.5 GBq) of [<sup>177</sup>Lu]Lu-DOTAGA.Glu.(FAPi)<sub>2</sub> administered over a median of 3 treatment cycles (range, 1–6 cycles). Patient responses were assessed using PERCIST in 6 patients and RECIST 1.1 in 9 patients. The primary endpoint was the disease control rate, defined as complete response, partial response, or stable disease, evaluated through morphologic, molecular, or clinical criteria. Secondary endpoints included progression-free survival, overall survival, and safety. <strong>Results:</strong> [<sup>177</sup>Lu]Lu-DOTAGA.Glu.(FAPi)<sub>2</sub> was generally well tolerated. Response assessment using PERCIST indicated a partial response in 33.3% of patients, whereas no objective response was observed in the response assessed with RECIST. Disease control rates were 50% and 22.3% with PERCIST and RECIST, respectively. Disease progression was documented in 7 patients, 3 of whom succumbed to disease-related complications. The median progression-free survival was approximately 5 mo (95% CI, 2.9–7.1 mo), and the median overall survival was 8 mo (95% CI, 5.5–10.5 mo). <strong>Conclusion:</strong> [<sup>177</sup>Lu]Lu-DOTAGA.Glu.(FAPi)<sub>2</sub> demonstrated clinical antitumor activity with a manageable safety profile in patients with sarcoma. Further studies with larger cohorts and combination therapies are warranted to optimize therapeutic efficacy and improve outcomes.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"14 1","pages":"jnumed.125.270186"},"PeriodicalIF":0.0,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144899196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clemens Mingels, Kevin J. Chung, Hande Nalbant, Yasser G. Abdelhafez, Naseem S. Esteghamat, Mehrad Rokni, Shervin Zoghi, Joseph M. Tuscano, Axel Rominger, Ramsey D. Badawi, Benjamin A. Spencer, Lorenzo Nardo
{"title":"Lymphoma Therapy Response Assessment with Low-Dose [18F]FDG Total-Body PET/CT","authors":"Clemens Mingels, Kevin J. Chung, Hande Nalbant, Yasser G. Abdelhafez, Naseem S. Esteghamat, Mehrad Rokni, Shervin Zoghi, Joseph M. Tuscano, Axel Rominger, Ramsey D. Badawi, Benjamin A. Spencer, Lorenzo Nardo","doi":"10.2967/jnumed.124.268841","DOIUrl":"https://doi.org/10.2967/jnumed.124.268841","url":null,"abstract":"<p>The improved sensitivity of total-body (TB) PET/CT offers the possibility of reducing injected activities. The aim of our study was to define a lower limit of reduced injected activities in [<sup>18</sup>F]FDG TB PET/CT for interim and end-of-treatment assessment of patients with lymphoma at 2 acquisition times. <strong>Methods:</strong> Twenty-four consecutive patients with lymphoma who were undergoing interim and end-of-treatment TB PET/CT were prospectively enrolled in this study. An [<sup>18</sup>F]FDG activity of 3.0 MBq/kg served as the reference standard (RS). Images simulating low doses of 1.0, 0.5, 0.25, and 0.125 MBq/kg were reconstructed at 1 and 2 h after injection. The coefficient of variation of the liver was assessed. Lymphoma lesions were segmented and semiquantitatively compared with the RS using the SUV. Additionally, metabolic tumor volume (MTV) for each lesion, patient-based total MTV, and total-lesion glycolysis (TLG) were analyzed. Semiquantitative parameters were normalized to the liver and blood pool by tumor-to-background ratios (TBRs) and contrast-to-noise ratios. Therapy response was assessed using Deauville criteria. <strong>Results:</strong> Overall, 191 lymphoma lesions were analyzed. SUV<sub>max</sub> demonstrated a trend toward a statistically significant increase in scans with reduced activity at 1 h after injection (6.28 ± 5.87 for RS vs. 7.76 ± 6.69 for 0.125 MBq/kg; <em>P</em> = 0.07) and 2 h after injection (7.14 ± 7.16 for RS vs. 8.67 ± 7.62 for 0.125 MBq/kg; <em>P</em> = 0.13). SUV<sub>peak</sub>, SUV<sub>mean</sub>, MTV, and TLG did not significantly differ between the reduced injected activities and the RS. The coefficient of variation for the liver increased significantly with decreasing injected activities (<em>P</em> < 0.01). The TBR for the liver did not differ significantly, whereas the TBR for the blood pool was significantly higher only for the lowest injected activity (<em>P</em> < 0.01) at 2 h after injection. The contrast-to-noise ratio significantly decreased with reduced activities. Deauville scores did not differ significantly, up to a dose of 0.25 MBq/kg at 1 h after injection and a dose of 1.0 MBq/kg at 2 h after injection. Below this limit, we noted significantly lower Deauville scores for reduced injected activities (<em>P</em> < 0.01). <strong>Conclusion:</strong> Reduction of injected activities with [<sup>18</sup>F]FDG TB PET/CT for therapy response assessment in patients with lymphoma may be possible and does not result in significant differences in MTV, TBR, or TLG. SUV<sub>max</sub> and Deauville scores were comparable to the RS to a lower limit of 0.25 MBq/kg at 1 h after injection and 1.0 MBq/kg at 2 h after injection.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144851368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Florian Schiller, Joachim Brumberg, Lars Frings, Joran Deschamps, Christopher Schmied, Florian Jug, Michael Mix, Philipp T. Meyer
{"title":"Clinical Validation of Deep Learning for Image Restoration of Ultra-Low-Count [18F]FDG PET for Dementia Diagnostics","authors":"Florian Schiller, Joachim Brumberg, Lars Frings, Joran Deschamps, Christopher Schmied, Florian Jug, Michael Mix, Philipp T. Meyer","doi":"10.2967/jnumed.124.269234","DOIUrl":"https://doi.org/10.2967/jnumed.124.269234","url":null,"abstract":"<p>Deep learning (DL) represents a promising technique for image restoration. We explored its ability to restore ultra-low-count [<sup>18</sup>F]FDG PET studies of the brain in subjects with dementia and in healthy subjects to allow for reduced scan durations or administered activities without compromising diagnostic performance. <strong>Methods:</strong> Various DL models using the content aware image restoration approach of CSBDeep toolbox (3D U-nets) were trained with subvolumes of 1,000 random subjects. On the basis of 10-min list-mode PET data after injection of 208 ± 10 MBq of [<sup>18</sup>F]FDG, we reconstructed reduced scan durations of 2 min, 1 min, 30 s, 20 s, and 10 s. The resulting models were applied to [<sup>18</sup>F]FDG PET scans of subjects with Alzheimer disease (<em>n</em> = 15), frontotemporal dementia (<em>n</em> = 14), and healthy controls (<em>n</em> = 13). We explored the effect of reduced scan times on individual regional measures in diagnostically relevant regions and on voxel-based group contrasts. Three independent readers rated all datasets with regard to assessability, diagnosis, and diagnostic confidence. <strong>Results:</strong> Individual mean regional [<sup>18</sup>F]FDG uptake remained largely unchanged. The SD strongly increased with shorter scan duration without application of DL (mean increase ≤ 48%), whereas it slightly decreased with DL (≥−7%). In group contrasts, the number of significant voxels strongly decreased with shorter scan time without DL (≥−41%), which was partially offset by DL (≥−27%). On visual reads, the fraction of assessable images steeply fell to only 4% (10-s scan) for scan durations below 2 min without DL, whereas every single image restored with DL was assessable. The diagnostic confidence continuously declined with shorter scan durations without DL, whereas diagnostic confidence only negligibly changed with DL (intermediate-to-high confidence ratings: 0%–54% vs. 80%–84%; 83% for the 10-min scan). The diagnostic accuracy of PET reads dropped from 90% to 4% without and remained high with DL (90%–93%; 90% for the 10-min scan). <strong>Conclusion:</strong> Our study demonstrates the compelling performance of DL to restore cerebral [<sup>18</sup>F]FDG PET datasets with ultra-low-count statistics for quantitative regional, voxel-based group, and clinical visual analyses. Consequently, DL enables a dramatic reduction of scan durations or administered activities (e.g., 10-min scan with 3.5 MBq, equivalent to ∼60 µSv) for [<sup>18</sup>F]FDG PET in patients with dementia and possibly other indications.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144851378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Orit Jacobson, Hongwei H. Zhang, Colleen P. Olkowski, Behnaz Ghaemi, Falguni Basuli, Jianfeng Shi, Meghan M. Bell, Farhat Parween, Sundar Ganesan, Thomas J. Esparza, Freddy E. Escorcia, Peter L. Choyke, Joshua M. Farber
{"title":"Monitoring T-Cell Activation in the Tumor Microenvironment by PET Imaging of the Chemokine CXCL9","authors":"Orit Jacobson, Hongwei H. Zhang, Colleen P. Olkowski, Behnaz Ghaemi, Falguni Basuli, Jianfeng Shi, Meghan M. Bell, Farhat Parween, Sundar Ganesan, Thomas J. Esparza, Freddy E. Escorcia, Peter L. Choyke, Joshua M. Farber","doi":"10.2967/jnumed.125.269795","DOIUrl":"https://doi.org/10.2967/jnumed.125.269795","url":null,"abstract":"<p>Noninvasive monitoring of immune responses is important for increasing the efficacy of cancer immunotherapy. Although several approaches exist, few methods directly report on T-cell activation. We aimed to develop a novel PET probe targeting C-X-C motif chemokine ligand 9 (CXCL9), a chemokine specifically induced by interferon gamma (IFN-γ), a cytokine that is produced by activated T cells and group 1 innate lymphoid cells. CXCL9 binds to glycosaminoglycans, which are expressed on cell surfaces and the extracellular matrix, to recruit or position cells in the tumor microenvironment. In cancers, expression of CXCL9 has been associated with improved survival and predicts and reflects responses to immunotherapy. The pronounced upregulation of CXCL9 by IFN-γ and CXCL9’s extracellular accessibility and site-specific accumulation make it a compelling biomarker for detecting T-cell activation. <strong>Methods:</strong> We developed a PET tracer targeting CXCL9 based on a high-affinity, antihuman CXCL9 nanobody (h2A12), which was isolated from a llama-derived phage display library and labeled with <sup>18</sup>F. The tracer was evaluated in cell culture, a subcutaneous xenograft model, and a humanized mouse model of T-cell engager therapy. <strong>Results:</strong> The h2A12 nanobody demonstrated high specificity for human CXCL9 (<em>K</em><sub>d</sub>, 4.07 ± 0.44 nM) with no cross-reactivity to related chemokines. In xenograft models, [<sup>18</sup>F]F-h2A12 showed significant uptake in CXCL9-expressing tumors (10.33 ± 1.23 %IA/g) compared with control tumors (0.25 ± 0.04 %IA/g) at 2 h after injection, with excellent tumor-to-background ratios. In the humanized model, T-cell engager therapy induced CXCL9 expression that peaked at day 7, corresponding with increased [<sup>18</sup>F]F-h2A12 uptake in treated tumors (2.61 ± 0.50 %IA/g) versus controls (0.67 ± 0.12 %IA/g). <strong>Conclusion:</strong> [<sup>18</sup>F]F-h2A12 PET imaging enables noninvasive visualization of CXCL9 expression as a biomarker of immune activation. This approach offers potential applications in monitoring immunotherapy responses and studying immune-mediated diseases.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144851321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maciej Kujawski, Eric Aniogo, Patty Wong, Susanta Hui, Hemendra Ghimire, Erasmus K. Poku, Paul J. Yazaki, Jeffrey Y.C. Wong, John E. Shively
{"title":"Combination Image-Guided and Antibody-Targeted α-Therapy Before Targeted Immunotherapy for Treatment of Solid Tumors","authors":"Maciej Kujawski, Eric Aniogo, Patty Wong, Susanta Hui, Hemendra Ghimire, Erasmus K. Poku, Paul J. Yazaki, Jeffrey Y.C. Wong, John E. Shively","doi":"10.2967/jnumed.125.270266","DOIUrl":"https://doi.org/10.2967/jnumed.125.270266","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.270266absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144851375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jeongryul Ryu, Sangwon Han, Tae-Kyung Robyn Yoo, Sae Byul Lee, Jisun Kim, Hee Jeong Kim, Il Yong Chung, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Hee Jin Lee, Gyungyub Gong, Dae Hyuk Moon
{"title":"Diagnostic Performance of 18F-Fluoroestradiol PET/CT for Axillary Lymph Node Metastasis in Invasive Lobular Carcinoma: A Prospective Feasibility Study","authors":"Jeongryul Ryu, Sangwon Han, Tae-Kyung Robyn Yoo, Sae Byul Lee, Jisun Kim, Hee Jeong Kim, Il Yong Chung, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Hee Jin Lee, Gyungyub Gong, Dae Hyuk Moon","doi":"10.2967/jnumed.125.269573","DOIUrl":"https://doi.org/10.2967/jnumed.125.269573","url":null,"abstract":"<p>Invasive lobular breast cancer (ILC) presents diagnostic challenges with conventional imaging modalities. We aimed to evaluate the diagnostic performance of <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) PET/CT for axillary lymph node (ALN) metastasis in ILC. <strong>Methods:</strong> This prospective feasibility study was conducted between August 2023 and August 2024. Eligible patients had newly diagnosed estrogen receptor–positive ILC, had confirmed or suspected ALN metastasis on physical examination or imaging, and were scheduled to undergo axillary surgery. The presence of metastasis in ipsilateral ALN on <sup>18</sup>F-FES PET/CT was assessed visually and semiquantitatively (SUV<sub>max</sub>) and compared with surgical specimens. <strong>Results:</strong> In total, 20 women were included in the analysis. Twelve patients had surgically proven ALN metastasis. On visual analysis, <sup>18</sup>F-FES PET/CT showed a sensitivity of 67% (8/12; 95% CI, 35%–90%) and a specificity of 100% (8/8; 95% CI, 63%–100%). All 4 false-negative cases had a single metastasis on the sentinel lymph node, with sizes of 1, 1.5, 6, and 6 mm. An unexpected <sup>18</sup>F-FES–positive ipsilateral internal mammary lymph node was detected in 1 patient. The median SUV<sub>max</sub> was 3.4 (interquartile range, 1.2–9.5) and 1.0 (interquartile range, 0.8–1.1) for metastatic and benign ALNs, respectively. With an optimal cutoff of at least 1.2, SUV<sub>max</sub> showed a sensitivity of 75% (9/12; 95% CI, 43%–95%) and a specificity of 100% (8/8; 95% CI, 63%–100%). The area under the receiver operating curve was 0.89 (95% CI, 0.75–1.00). Three of 4 patients with false-negative fine-needle aspiration results for ALN were positive on <sup>18</sup>F-FES PET/CT. <strong>Conclusion:</strong> <sup>18</sup>F-FES PET/CT had excellent specificity and moderate sensitivity for detecting ALN metastasis in ILC, suggesting its potential as a valuable staging modality for early ILC.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144851380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
René R. Sevag Packard, Christopher Buckley, C. David Cooke, Jonathan B. Moody, Jennifer M. Renaud, Piotr Slomka, David Thompson, Serge D. Van Kriekinge, Kenneth F. Van Train, Kristen A. Wangerin, Jamshid Maddahi
{"title":"Comparison, Agreement, and Significance Cutoffs of 18F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages","authors":"René R. Sevag Packard, Christopher Buckley, C. David Cooke, Jonathan B. Moody, Jennifer M. Renaud, Piotr Slomka, David Thompson, Serge D. Van Kriekinge, Kenneth F. Van Train, Kristen A. Wangerin, Jamshid Maddahi","doi":"10.2967/jnumed.124.269398","DOIUrl":"https://doi.org/10.2967/jnumed.124.269398","url":null,"abstract":"<p><sup>18</sup>F-flurpiridaz is a novel PET myocardial perfusion radiotracer with a high myocardial extraction fraction and low positron range, providing high-resolution images. Additionally, the linear relationship between <sup>18</sup>F-flurpiridaz myocardial extraction and myocardial blood flow (MBF) over a wide range of flow values permits accurate MBF measurement. Several groups have developed strategies to quantitate <sup>18</sup>F-flurpiridaz MBF with methodologic differences. These methods have not previously undergone head-to-head comparisons. <strong>Methods:</strong> Three methods of <sup>18</sup>F-flurpiridaz MBF quantitation were compared using Emory Cardiac Toolbox (ECTb; Syntermed), 4DM (INVIA), and Quantitative PET (QPET; Cedars-Sinai) software. All evaluable pharmacologic stress patients from the phase 3 <sup>18</sup>F-flurpiridaz PET trial (NCT03354273) of <sup>18</sup>F-flurpiridaz were included (<em>n</em> = 405). We adopted Bland–Altman plots to determine absolute differences between MBF quantitative methods, Fleiss κ for agreement across software packages, and Cohen κ for agreement of pairwise comparisons. Diagnostic performances of stress MBF and myocardial flow reserve (MFR) were determined by performing receiver-operating-characteristic analysis for areas under the curve (AUCs), using quantitative invasive coronary angiography as the reference standard. <strong>Results:</strong> Differences in mean stress MBF and MFR between methods across coronary territory distributions ranged from 0.23 to 0.29 mL/min/g and from 0.37 to 0.40 mL/min/g for ECTb and 4DM, respectively; from 0.09 to 0.11 mL/min/g and from 0.36 to 0.38 mL/min/g for ECTb and QPET, respectively; and from 0.25 to 0.26 mL/min/g and from 0.39 to 0.40 mL/min/g for QPET and 4DM, respectively. There was substantial agreement across software packages, with the Fleiss κ ranging from 0.77 to 0.79 and 0.72 to 0.75 for stress MBF and MFR, respectively. Similar results were found in pairwise comparisons. For coronary artery territories with at least 70% stenosis, median stress MBF and MFR AUCs were 0.73–0.74 and 0.71–0.73, respectively, when evaluated on a per-patient basis, and 0.75–0.77 and 0.74–0.75, respectively, in pooled coronary distributions on a per-vessel basis across all methods. <strong>Conclusion:</strong> All software packages demonstrated high agreement and similar <sup>18</sup>F-flurpiridaz MBF quantitation, paving the way for the interoperability of these platforms in clinical practice.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"736 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144797407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wenpeng Huang, Liming Li, Fangfang Chao, Qi Yang, Jason C. Mixdorf, Jonathan W. Engle, Jessica C. Hsu, Lei Kang, Weibo Cai
{"title":"[64Cu]Cu-NOTA-EV-F(ab′)2 Enables Same-Day Immuno-PET Imaging of Nectin-4 in Triple-Negative Breast and Urothelial Bladder Cancers","authors":"Wenpeng Huang, Liming Li, Fangfang Chao, Qi Yang, Jason C. Mixdorf, Jonathan W. Engle, Jessica C. Hsu, Lei Kang, Weibo Cai","doi":"10.2967/jnumed.125.270132","DOIUrl":"https://doi.org/10.2967/jnumed.125.270132","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.270132absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144797412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Roos M. Rikken, Elsmarieke van de Giessen, Joachim Brumberg, Richard Aarnio, Merijn Joling, Anton Forsberg Morén, Vera Kerstens, Mohammad M. Moein, Sangram Nag, Christer Halldin, Patrik Fazio, Dareia S. Roos, Henk W. Berendse, Michael Kassiou, Saara Wahlroos, Merja Haaparanta-Solin, Vesa Oikonen, Robert C. Schuit, Ronald Boellaard, Albert D. Windhorst, Andreas H. Jacobs, Adriaan A. Lammertsma, Juha O. Rinne, Andrea Varrone, Sandeep S.V. Golla
{"title":"Imaging Proinflammatory Microglia in Parkinson Disease Using [11C]SMW139 PET: A Multicenter Study","authors":"Roos M. Rikken, Elsmarieke van de Giessen, Joachim Brumberg, Richard Aarnio, Merijn Joling, Anton Forsberg Morén, Vera Kerstens, Mohammad M. Moein, Sangram Nag, Christer Halldin, Patrik Fazio, Dareia S. Roos, Henk W. Berendse, Michael Kassiou, Saara Wahlroos, Merja Haaparanta-Solin, Vesa Oikonen, Robert C. Schuit, Ronald Boellaard, Albert D. Windhorst, Andreas H. Jacobs, Adriaan A. Lammertsma, Juha O. Rinne, Andrea Varrone, Sandeep S.V. Golla","doi":"10.2967/jnumed.125.269671","DOIUrl":"https://doi.org/10.2967/jnumed.125.269671","url":null,"abstract":"<p>Several translocator protein (TSPO) PET studies have shown increased glial cell density in Parkinson disease (PD); however, TSPO tracers are not able to differentiate between proinflammatory and antiinflammatory processes, information that is crucial for the development and evaluation of therapies. We used [<sup>11</sup>C]SMW139 PET to target the P2X7 receptor, which is expressed on proinflammatory microglia, to investigate proinflammatory signals in PD. <strong>Methods:</strong> Patients with PD (<em>n</em> = 15) and healthy controls (HCs) (<em>n</em> = 15) were included in this multicenter study. All participants underwent a 90-min [<sup>11</sup>C]SMW139 PET scan with continuous online and manual blood sampling. A 2-tissue compartment model with dual-input curves (both unchanged radiopharmaceutical [i.e., parent] and radiometabolites) was used to quantify [<sup>11</sup>C]SMW139. The distribution volume of the parent (<em>V</em><sub>Tp</sub>) was considered the main parameter of interest. Differences in [<sup>11</sup>C]SMW139 <em>V</em><sub>Tp</sub> between patients with PD and HCs were assessed using linear mixed models with post hoc testing. Regions of interest determined a priori included the putamen, caudate nucleus, brain stem, and whole cortex. Associations between motor symptom severity, as measured by the score on Part III (Motor Evaluation) of the Unified Parkinson’s Disease Rating Scale, disease duration, and [<sup>11</sup>C]SMW139 <em>V</em><sub>Tp</sub> were assessed using linear regression. <strong>Results:</strong> In the a priori regions of interest, patients with PD had a significantly higher <em>V</em><sub>Tp</sub> in the putamen (β = 0.04; <em>P</em> = 0.046) and whole cortex (β = 0.04; <em>P</em> = 0.043) compared with those of HCs. In an exploratory analysis, patients with PD also had a higher <em>V</em><sub>Tp</sub> in the orbitofrontal cortex (β = 0.04; <em>P</em> = 0.041) compared with that of HCs. There was no significant association between <em>V</em><sub>Tp</sub> and symptom severity (brain stem: β = −0.002; <em>P</em> = 0.084; caudate nucleus: β = −0.002; <em>P</em> = 0.164; putamen: β = −0.002; <em>P</em> = 0.265; whole cortex: β = −0.002; <em>P</em> = 0.119) or disease duration (brain stem: β = −0.01; <em>P</em> = 0.055; caudate nucleus: β = −0.005; <em>P</em> = 0.282; putamen: β = −0.01; <em>P</em> = 0.113; whole cortex: β = −0.007; <em>P</em> = 0.217) in patients with PD. <strong>Conclusion:</strong> Patients with PD showed increased P2X7 receptor binding in the putamen and brain cortex, as assessed by [<sup>11</sup>C]SMW139 PET, suggesting the presence of increased levels of proinflammatory microglia.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144797410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}